An update on methotrexate

Current Opinion in Rheumatology

Volumn 21, Issue 3, 2009, Pages 216-223

  Braun, Juergen ^a   Rau, Rolf ^b  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b NONE   (Germany)

Author keywords

Disease modifying antirheumatic agents; Genetic polymorphisms in the folate metabolic pathway; Long term safety; Methotrexate; Methotrexate polyglutamates; Subcutaneous application

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFLAMMATION; LIVER DISEASE; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT RESPONSE; PATHOPHYSIOLOGY; RHEUMATIC DISEASE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; METHOTREXATE; PHARMACOGENETICS; RHEUMATIC DISEASES;

EID: 67650156848     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328329c79d     Document Type: Review

References (51)

1. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312:818-822.
2. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46:1443-1450.
3. Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998; 37:1220-1226.
4. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14-21.
5. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-1177.
6. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extraarticular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008;24:469-480.
7. Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58:3675-3683. Important new insights into the working mechanisms of MTX.
8. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis 2008. [Epub ahead of print] Evidence-based recommendations on the clinical use of MTX.
9. Sokka T, Pincus T. Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008; 47:1543-1547.
10. Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008; 58:1310-1317. A randomized controlled trial (RCT) providing evidence that tight control is more important that early combination therapy.
11. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:59-64. The study shows that the early intensive suppression of inflammation is most relevant for outcome and suggests that the step-down strategy is superior to the step-up approach.
12. van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008; 67:1574-1577. This study also suggests that the early intensive suppression of inflammation is very relevant for outcome.
13. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2008; 58 (2 Suppl):S126-S135. A RCT providing evidence that early intensive therapy and early use of biologic agents is a superior strategy.
14. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56:1424-1432.
15. Visser K, Verpoort KN, van Dongen H, et al. Pretreatment serum levels of anticyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis 2008; 67:1194-1195.
16. Fortin PR, Abrahamowicz M, Ferland D, et al., Canadian Network For Improved Outcomes in Systemic Lupus Erythematosus. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008; 59:1796-1804. A RCT providing evidence that MTX is a steroid-sparing agent in lupus patients with musculoskeletal symptoms.
17. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007; 66:419-421.
18. Braun J, Sieper J. What is the most important outcome in ankylosing spondylitis? Rheumatology (Oxford) 2008; 47:1738-1740.
19. Hider SL, Silman AJ, Thomson W, et al. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis 2009; 68:57-62.
20. Braun J, Kästner P, Flaxenberg P, et al., MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58:73-81. A RCT providing evidence that subcutaneous administration of MTX is more efficacious.
21. Bharadwaj A, Agrawal S, Batley M, Hammond A. Use of parenteral methotrexate significantly reduces the need for biological therapy. Rheumatology (Oxford) 2008; 47:222.
22. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2008. [Epub ahead of print]
23. Bernatsky S, Ehrmann Feldman D. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Québec, Canada. Drugs Aging 2008; 25:879-884.
24. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:249-255.
25. Kremer JM. Methotrexate treatment of rheumatic diseases: can we do better? Arthritis Rheum 2008; 58:3279-3282.
26. van Roon JA, Jacobs K, Verstappen S, et al. Reduction of serum interleukin 7 levels upon methotrexate therapy in early rheumatoid arthritis correlates with disease suppression. Ann Rheum Dis 2008; 67:1054-1055.
27. Herman S, Zurgil N, Langevitz P, et al. Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients. Clin Exp Rheumatol 2008; 26:317-323.
28. Hornung N, Ellingsen T, Attermann J, et al. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol 2008; 35:1709-1715.
29. Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:3299-3308. An experimental study explaining some of the variability of response to MTX.
30. Fiehn C, Kratz F, Sass G, et al. Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann Rheum Dis 2008; 67:1188-1191. An experimental study suggesting that there are pharmacological possibilities to improve MTX efficacy.
31. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008; 9:439-451.
32. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-2774.
33. Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006; 54:607-612.
34. Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35:572-579.
35. Dervieux T. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference? J Rheumatol 2008; 35:550-552.
36. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008; 64:1057-1068.
37. Zeng QY, Wang YK, Xiao ZY, Chen SB. Pharmacogenetic study of 5,10-methylenetetrahydrofolate reductase C677T and thymidylate synthase 3R/2R gene polymorphisms and methotrexate-related toxicity in Chinese Han patients with inflammatory arthritis. Ann Rheum Dis 2008; 67:1193-1194.
38. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006; 54:1087-1095.
39. James HM, Gillis D, Hissaria P, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol 2008; 35:562-571.
40. Warren RB, Smith RL, Campalani E, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009;160:438-441.
41. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexateassociated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2008. [Epub ahead of print]
42. Rajakulendran S, Gadsby K, Deighton C. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified? Musculoskeletal Care 2008; 6:233-246.
43. Pieringer H, Stuby U, Biesenbach G. The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 2008; 27:1217-1220.
44. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008; 59:794-799. An epidemiological studysuggesting that sun exposure and MTX intake may increase the melanoma risk in Australian RA patients.
45. Abásolo L, Júdez E, Descalzo MA, et al., EMECAR study group. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008; 37:388-397.
46. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008; 168:378-381.
47. Rizzi R, Curci P, Delia M, et al. Spontaneous remission of 'methotrexateassociated lymphoproliferative disorders' after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 2008. [Epub ahead of print]
48. Tokuda H, Sakai F, Yamada H, et al. Clinical and radiological features of pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med 2008; 47:915-923.
49. Sommer W, Ganiere V, Gachoud D, et al. Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. Scand J Rheumatol 2008; 37:306-309.
50. Collins K, Aspey H, Todd A, et al. Methotrexate pneumonitis precipitated by switching from oral to parenteral administration. Rheumatology (Oxford)2008; 47:109-110.
51. Gaffo AL, Alarcón GS. Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008;168:1927-1928.